Logo ICIUM2011

Conference Agenda

Overview and details of the sessions of this conference. Please select a date or room to show only sessions at that day or location. Please select a single session for detailed view (with abstracts and downloads if available).

 
Session Overview
Session
Methods 5: Using Market Intelligence Information for Pharmaceutical Policy Analysis
Time: Friday, 18/Nov/2011: 9:00am - 11:00am
Session Moderator: Veronika J. Wirtz, National Institute of Public Health, Mexico, Mexico
Session Moderator: Murray Aitken, IMS Institute for Healthcare Informatics, United States of America
Session Rapporteur: Laura Faden Garabedian, Harvard Medical School and Harvard Pilgrim Health Care Institute, United States of America
Location: Jasper Auditorium

Presentations

Evolution of the Generic Medicines Market in Brazil, 1998-2010: Antihypertensives, Antidiabetics, and Antibiotics

Andréa Dâmaso Bertoldi1, Peter Stephens2, Anita K. Wagner3, Dennis Ross-Degnan3

1Universidade Federal de Pelotas. Pelotas, RS, Brazil; 2IMS Health. London, UK; 3Harvard Medical School and Harvard Pilgrim Health Care Institute. Boston, US

Problem Statement: Generic medicines were launched in Brazil in February 2000 after implementation of the Generic Medicines Policy in 1999. Since then, three types of medicines have been available in the market: originator brands, unbranded generics, and similares (non-originator brands). In Brazil, all generic medicines must be commercialized with no brand and they are the only group of medicines which are considered interchangeable with the originator brand; similares are all the other brand medicines available in the market.

Objectives: To describe changes in market share of selected originator products, similares’ and generics over time, following the 1999 Brazilian generics law.

Design: Interrupted time series.

Setting: Longitudinal data on sales by wholesalers to retail pharmacies in Brazil of antihypertensives, antidiabetics, and antibiotics collected by IMS Health between 1998 and 2010.

Policies: Generics policy (February 1999).

Outcome Measures: Proportion, by originator, similares, and generic products within three therapeutic classes (antihypertensives, antidiabetics, and antibiotics), of the total volume sold by quarter (unit sales volume divided by the total volume of units sold in the market) from the second quarter of 1998 (period 1) through the first quarter of 2010 (period 48).

Results: We analyzed 8,559 products marketed in Brazil between 1998 and 2010; 448 medicines used in diabetes, 2,113 medicines used to treat hypertension and 2,825 systemic antibacterials. Antidiabetics—Starting in period 1, the number of manufacturers producing similares rose rapidly, but this changed at period 30. From the introduction of generics in the market (period 14), the number of manufacturers producing them constantly increased. At period 1, originator brands corresponded to around 85% of the volume of sales. From period 1 to period 14, the volume of similares sales rose and originator brands sales declined. The sales volume of originator brands continued to decline, and he sales volume of similares no longer increased. At the end of the period, generics made up half of the sales, similares accounted for just over 30%, and originator brands to just below 20%. Antibiotics—At any point in time, there were more manufacturers producing similares than any other type of medicine. The number of manufacturers producing generics, on the other hand, rose during the whole period under study. The volume of sales changed very rapidly after the introduction of generics in the market. In period 9, the first generic antibiotics became available in the market. In about one year, generics overtook originator brands and similares in terms of market share. The market share of originator brands declined over time. The market shares of generics and similares in period 48 were about 60% and 35%, respectively. Antihypertensives—In period 9, the first generics were launched in the market, and the number of manufacturers producing generics increased over time. However, the number of manufacturers producing ‘similares’ was consistently higher than that of generics. The volume of sales of both similares and generics tended to increase until period 32. From that period onwards, volume of generics sales continued to increase while similares sales tended to stabilize.

Conclusions: Using data from IMS Health, it is possible to evaluate the impact of the Generic Medicines policy in the Brazilian market share. Sales of similares and particularly originator brands decreased substantially following the launch of generics in the Brazilian market.

Funding Source:

IMS Health provided data in kind. Drs. Wagner and Ross-Degnan were supported by a grant from the World Health Organization for the development of the ICIUM2011 scientific program.

998-Bertoldi-_a.pdf
998-Bertoldi-_b.pptx
998-Bertoldi-_c.pdf

Gender and Access to Medicines in 15 Low- and Middle-Income Countries: Does Physician Prescribing for Men and Women Differ?

Peter Neil Stephens

IMS HEALTH, United Kingdom

See poster number 954

1292-Stephens-_b.pptx
1292-Stephens-_c.pdf

Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC

Stefan Ziegele1, Peter Stephens2

1IMS Health, Germany; 2IMS Heatlh, UK

1256-Ziegele-_b.ppt
1256-Ziegele-_c.pdf